Exisulind: Difference between revisions
m (Protected "Exisulind": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +)) |
||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 6: | Line 6: | ||
[[Category:Chemotherapeutic agents]] | [[Category:Chemotherapeutic agents]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 02:29, 9 August 2012
WikiDoc Resources for Exisulind |
Articles |
---|
Most recent articles on Exisulind |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Exisulind at Clinical Trials.gov Clinical Trials on Exisulind at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Exisulind
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Exisulind Discussion groups on Exisulind Directions to Hospitals Treating Exisulind Risk calculators and risk factors for Exisulind
|
Healthcare Provider Resources |
Causes & Risk Factors for Exisulind |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Exisulind is a drug used to treat cancer. It acts by inhibiting the enzyme cyclic guanosine monophosphate phosphodiesterase. Tademark by OSI Pharmaceuticals is Aptosyn. Template:WH Template:WS